Cognitive function and quality of life in ovarian cancer

被引:45
作者
Correa, Denise D. [1 ]
Hess, Lisa M. [2 ,3 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Indiana Univ Sch Med, Dept Publ Hlth, Indianapolis, IN USA
[3] Indiana Univ Sch Med, Dept Obstet, Indianapolis, IN USA
[4] Indiana Univ Sch Med, Dept Gynecol, Indianapolis, IN USA
关键词
Cognitive function; Quality of life; Ovarian cancer; PEGYLATED LIPOSOMAL DOXORUBICIN; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; PHASE-III; SYSTEMIC CHEMOTHERAPY; PLUS CARBOPLATIN; OLDER-ADULTS; SURVIVORS; WOMEN; PERFORMANCE;
D O I
10.1016/j.ygyno.2011.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. As advances in treatment have prolonged survival for many patients with ovarian cancer, there has been growing interest in assessing the adverse effects of disease and treatment. The aim of this study was to review the literature on cognitive function and quality of life (QOL) in this population. Methods. A review of published studies including formal assessment of neurocognitive functions and self-reported domains of quality of life, with an emphasis on cognitive function, was performed. Results. The small number of studies including formal evaluations of neurocognitive function suggests that many ovarian cancer patients experience cognitive difficulties associated with their disease and treatment. Several studies described declines in self-reported cognitive function that may impact QOL, but the results were not consistent across studies. Conclusions. Adequately powered longitudinal studies including formal neurocognitive and QOL assessments are needed to advance our understanding of the incidence of cognitive dysfunction and its impact on functional ability and QOL in ovarian cancer patients. These research efforts may ultimately contribute to treatment decision-making through the identification of vulnerable patients, and to the development of appropriate intervention strategies to improve cognitive function and QOL. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:404 / 409
页数:6
相关论文
共 68 条
[1]   The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy [J].
Ahles, TA ;
Saykin, AJ ;
Noll, WW ;
Furstenberg, CT ;
Guerin, S ;
Cole, B ;
Mott, LA .
PSYCHO-ONCOLOGY, 2003, 12 (06) :612-619
[2]   Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma [J].
Ahles, TA ;
Saykin, AJ ;
Furstenberg, CT ;
Cole, B ;
Mott, LA ;
Skalla, K ;
Whedon, MB ;
Bivens, S ;
Mitchell, T ;
Greenberg, ER ;
Silberfarb, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :485-493
[3]   Candidate mechanisms for chemotherapy-induced cognitive changes [J].
Ahles, Tim A. ;
Saykin, Andrew J. .
NATURE REVIEWS CANCER, 2007, 7 (03) :192-201
[4]  
[Anonymous], COCHRANE DATABASE SY
[5]  
[Anonymous], J BIOL
[6]  
[Anonymous], EUR J CANC
[7]  
[Anonymous], BREAST CANC RES TREA
[8]   A review of issues surrounding quality of life among women with ovarian cancer [J].
Arriba, Lucybeth Nieves ;
Fader, Amanda Nickles ;
Frasure, Heidi E. ;
von Gruenigen, Vivian E. .
GYNECOLOGIC ONCOLOGY, 2010, 119 (02) :390-396
[9]   Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer [J].
Bender, Catherine M. ;
Sereika, Susan M. ;
Brufsky, Adam M. ;
Ryan, Christopher M. ;
Vogel, Victor G. ;
Rastogi, Priya ;
Cohen, Susan M. ;
Casillo, Frances E. ;
Berga, Sarah L. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (06) :995-998
[10]   Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study [J].
Bezjak, A ;
Tu, DS ;
Bacon, M ;
Osoba, D ;
Zee, B ;
Stuart, G ;
Roy, JA ;
Piccart, M ;
Eisenhauer, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4595-4603